{"entity":{"id":"nct07153965","kind":"trial","name":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT07153965 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 47 participants, started 2025-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: Sacituzumab Tirumotecan plus Tagitanlimab. Conditions listed: Triple Negative Breast Cancer (TNBC); PD-L1 Positive. Triple-negative eligibility wording from the registry: \"* Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or other pathological specimens, including:\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07153965","url":"https://clinicaltrials.gov/study/NCT07153965"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07153965","phase":"2","setting":"An Open-label, Single-arm, Multicenter Phase II Study of Sacituzumab Tirumotecan (Sac-TMT) Plus Tagitanlimab in Previously Treated PD-L1-positive Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":47,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07153965/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}